TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00004847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ([18F]-DOPA)
Description: is L 3, 4 dihydroxyphenylalanine (L-DOPA) labeled with the radioactive isotope 18F. In general, PPGLs belong to the group of neuroendocrine tumors. This heterogeneous group of tumors takes up amino acids, transforms them into biogenic amines (dopamine and serotonin) by decarboxylation and stores the amines in vesicles. L DOPA is a precursor of catecholamines (dopamine, norepinephrine and epinephrine). Epinephrine conversion to dopamine is catalyzed by the aromatic amino acid decarboxylase. According to previous and current studies, \[18F\]-DOPA PET is highly sensitive and specific for detection of PHEO/PGL67-69. However, there are only a few reports in the literature using \[18F\]-DOPA as a PET agent and particularly for patients with metastatic PPGLs. PET imaging will be done together with either a CT, an MRI or both modalities.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ([18F]-6F-DA)
Description: is an imaging agent developed at the NIH, that may improve specificity and sensitivity in the localization of PPGLs. \[18F\]-6F-DA enters cells via the membrane norepinephrine transporter. Once inside cells, \[18F\]-6F-DA is translocated via the vesicular monoamine transporter into storage vesicles, where the radioactivity is concentrated. After injection of \[18F\]-6F-DA, the much faster disappearance of \[18F\]-6F-DA-derived radioactivity from the bloodstream and non-neuronal cells than from chromaffin cells should enable rapid visualization of PPGLs by PET scanning.
Study: NCT01326156

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Knee arthroplasty
Description: Comparison of patellofemoral arthroplasty versus conventional total knee arthroplasty in cases of isolated patellofemoral osteoarthritis.
Study: NCT01853579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: The intervention will start with Levothyroxine 50 µg daily (reduced to 25 µg in subjects \<50Kg body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) versus matching placebo; at 3 months if the serum TSH level is \<0.4 mU/L dose will be reduced by 25 µg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6mUL, additional 25 µg. The process will be repeated at 12 months then annually. Mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine that will be prescribed is 150μg (after 4 increments of 25μg at 3 months, 1, 2 and 3 years; from the starting dose of 50μg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
Study: NCT00656149

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Telerehabilitation of hand function
Description: 6 weeks, 1 hr/day FES-assisted exercise therapy on a workstation, supervised over the Internet.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional exercise therapy
Description: For one hour per day subjects perform range-of-motion tasks with a wristlet weight (20 min), precision tasks with a computer mouse (20 min) and receive cyclical electrical stimulation of hand muscles (20 min).
Study: NCT04624386

Intervention type: OTHER
Intervention: Thiol disulfide level
Description: Venous blood is collected from all subjects and thiol disulfide levels will be determined from the serum samples obtained from the venous blood.

Intervention type: OTHER
Intervention: Thiol disulfide level
Description: Venous blood is collected from all subjects and thiol disulfide levels will be determined from the serum samples obtained from the venous blood.
Study: NCT02606981

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Water chlorination by the Flogenic
Description: The chlorine doser delivers a constant amount of chlorine into water as it flows into a holding tank. The water is then piped to public and private taps.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Active control, vitamin C dosing into water
Description: The control group will receive a vitamin C dosing device that looks identical to the intervention chlorine doser installed in the holding tank that feeds their shared water access point.
Study: NCT02192060

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test - Using of a suspension containing Triclosan
Description: The participants should have used only the suspension containing Triclosan during 5 days and have stopped with their biofilm control homemade procedures.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control - Using of a suspension without Triclosan
Description: The participants should have used only the Placebo suspension during 5 days and have stopped with their biofilm control homemade procedures.
Study: NCT03139981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN002
Description: Daily dose of ASN002 for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN002
Description: Daily dose of ASN002 for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN002
Description: Daily dose of ASN002 for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN002
Description: Daily dose of ASN002 for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Placebo for ASN002 for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Placebo for ASN002 for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Placebo for ASN002 for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Placebo for ASN002 for 28 days
Study: NCT03894982

Intervention type: OTHER
Intervention: Group Classes
Description: Family Learning on Asthma Topics classes will aim to emphasize, encourage, and support teaching methods that include standardized instructions. There will be three topics lasting approximately 45 minutes: General Asthma Knowledge; Asthma Triggers, Medications, and Self-Management. These topics were chosen based on the EPR-3 guideline recommendations to ensure the continuity of messaging. Each class size will be approximately 8 persons and will be taught by a Certified Asthma Educator (AE-C) and will be held in the Family Learning Center at the Children's Hospital Colorado. Classes will be taught in both English and Spanish.

Intervention type: OTHER
Intervention: Group Classes
Description: Family Learning on Asthma Topics classes will aim to emphasize, encourage, and support teaching methods that include standardized instructions. There will be three topics lasting approximately 45 minutes: General Asthma Knowledge; Asthma Triggers, Medications, and Self-Management. These topics were chosen based on the EPR-3 guideline recommendations to ensure the continuity of messaging. Each class size will be approximately 8 persons and will be taught by a Certified Asthma Educator (AE-C) and will be held in the Family Learning Center at the Children's Hospital Colorado. Classes will be taught in both English and Spanish.

Intervention type: OTHER
Intervention: Group Classes
Description: Family Learning on Asthma Topics classes will aim to emphasize, encourage, and support teaching methods that include standardized instructions. There will be three topics lasting approximately 45 minutes: General Asthma Knowledge; Asthma Triggers, Medications, and Self-Management. These topics were chosen based on the EPR-3 guideline recommendations to ensure the continuity of messaging. Each class size will be approximately 8 persons and will be taught by a Certified Asthma Educator (AE-C) and will be held in the Family Learning Center at the Children's Hospital Colorado. Classes will be taught in both English and Spanish.
Study: NCT02003638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin
Description: Niacin titrated to 6000 mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo provided in the same pill quantity as niacin arm
Study: NCT02581046

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phacomulsification lens removal cataract surgery without Intraocular lens(IOL) implantation at the age of 3month of the patients
Description: The surgical timing of phacoemulsification is perform at the age of 3 month of the patients. During Phacoemulsification, viscoelastic materials and anterior lens capsule are used to protect corneal endothelial cells.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phacomulsification lens removal cataract surgery without Intraocular lens(IOL) implantation at the age of 6 month of the patients
Description: The surgical timing of phacoemulsification is perform at the age of 6 month of the patients. During Phacoemulsification, viscoelastic materials and anterior lens capsule are used to protect corneal endothelial cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subconjunctival dexamethasone and general anesthesia
Description: All patients received subconjunctival dexamethasone (2 mg) during surgery, and all surgeries were performed under general anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subconjunctival dexamethasone and general anesthesia
Description: All patients received subconjunctival dexamethasone (2 mg) during surgery, and all surgeries were performed under general anesthesia.
Study: NCT03478475

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol (Euro-Pharm International, Canada)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill (microcrystalline cellulose 66.3%, starch 33.2%, magnesium stearate 0.5%)
Study: NCT03764631

Intervention type: DRUG
Intervention: Empagliflozin
Description: Drug

Intervention type: DRUG
Intervention: Dipeptidyl-peptidase 4 (DPP-4) inhibitors
Description: Dipeptidyl-peptidase 4 - Drug
Study: NCT00801788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone hydrochloride
Description: Extended release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone hydrochloride
Description: Extended release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone hydrochloride
Description: Extended release tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone hydrochloride
Description: Extended release tablet
Study: NCT03299881

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Nerve Stimulator (TENS)
Description: The Elira wearable patch system is a RF coupled, wearable transcutaneous electrical nerve stimulator (TENS) device controlled via Bluetooth by a smart phone unit running a custom application which directs therapy from the patch within safe limits set by a clinician and also includes a weight loss diary.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet & Exercise
Description: Subjects to be instructed on a healthy 1200 calorie diet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet & Exercise
Description: Subjects to be instructed on a healthy 1200 calorie diet.
Study: NCT03593343

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Overnight fasting duration
Description: Subjects will adhere to overnight fasting protocol for 6 days

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Overnight fasting duration
Description: Subjects will adhere to overnight fasting protocol for 6 days
Study: NCT01628679

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical therapy treatment
Description: Subjects will be given pelvic floor motor control,proprioception and relaxation exercises. This will be with and without the use of external surface Electromyography (EMG) biofeedback. Education will also be given on pain management, female sexual response and vestibulodynia. Subjects will also practice inserting vaginal inserts of graduating diameter into their vaginas, practicing the skills learned in physical therapy sessions.
Study: NCT02965183

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Temperature measurements
Study: NCT04147897

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FOCUS
Description: FOCUS is a self management mHealth application for people with serious mental illness.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FOCUS
Description: FOCUS is a self management mHealth application for people with serious mental illness.
Study: NCT01509976

Intervention type: OTHER
Group type: OTHER
Intervention: triclosan/triclocarban-containing personal care products
Description: Subjects will be randomly assigned to one of two arms with either triclosan/triclocarban-containing personal care products or products without triclosan/triclocarban. After 5 months, each subject will cross over to the other arm.

Intervention type: OTHER
Group type: OTHER
Intervention: triclosan/triclocarban-containing personal care products
Description: Subjects will be randomly assigned to one of two arms with either triclosan/triclocarban-containing personal care products or products without triclosan/triclocarban. After 5 months, each subject will cross over to the other arm.
Study: NCT03871257

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib Sulfate
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV or IV push
Study: NCT03333096

Intervention type: DEVICE
Group type: OTHER
Intervention: Ocusweep test battery
Description: Ocusweep test battery to measure vision, visual system and cognitive performance including attention~(Comparison of Ocusweep system to conventional neuropsychological test methods)~(With the help of Ocusweep tests, information is obtained about the functioning of the whole visual system - from the ability of the eye to see to the efficiency of the brain to process visual information and the accuracy of eye movements)

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Neuropsychological test battery
Description: Conventional neuropsychological test battery to measure executive functioning, attention, visuoconstructive abilities and processing speed
Study: NCT01309672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone acetate
Description: 1,000 mg, oral (on an empty stomach at least 2 hours after or 1 hour before eating); taken daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg, oral, 5 mg twice daily
Study: NCT01254864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: 1000 mg by mouth each day of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: 1000 mg by mouth each day of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: 1000 mg by mouth each day of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg by mouth twice daily of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg by mouth twice daily of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg by mouth twice daily of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 37.5 mg by mouth daily for two weeks followed by a week of rest in a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: 100 mg by mouth each day of a 28 day cycle.
Study: NCT04397653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: In the intervention arm evolocumab 140 mg subcutaneous every 2 weeks will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the placebo arm placebo subcutaneous every 2 weeks will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Ezetimibe 10 mg daily will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia in both the placebo arm (plus placebo) and in the intervention arm (plus evolocumab)
Study: NCT02405364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib/Lenalidomide/Dexamethasone
Description: Induction:Carfilzomib/Lenalidomide/Dexamethasone (4 cycles every 28 days) Stem Cell harvest: HD Cyclophosphamide Intensification: HD Melphalan Consolidation:Carfilzomib/Lenalidomide/Dexamethasone (4 cycles every 28 days) Maintenance: Lenalidomide (13 cycles)
Study: NCT04076059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Oral
Study: NCT01106859

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zopiclone
Description: 7.5 mg tablet by mouth. Zopiclone is a commonly used hypnotic in Europe that is known to impair driving in the morning 9 hours after dosing.
Study: NCT04076059

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Description: All participants were required to maintain ADT during study treatment, either using luteinizing hormone-releasing hormone (LHRH) agonist/antagonist or having a history of bilateral orchiectomy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Androgen deprivation therapy (ADT)
Description: All participants were required to maintain ADT during study treatment, either using luteinizing hormone-releasing hormone (LHRH) agonist/antagonist or having a history of bilateral orchiectomy.
Study: NCT01106859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolpidem tartrate sublingual tablet
Description: 3.5 mg zolpidem tartrate sublingual tablet taken either 3 or 4 hours prior to driving. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolpidem tartrate sublingual tablet
Description: 3.5 mg zolpidem tartrate sublingual tablet taken either 3 or 4 hours prior to driving. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (sublingual tablet)
Description: Placebo matching zolpidem tartrate sublingual tablet taken either 3 or 4 hours prior to driving. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (sublingual tablet)
Description: Placebo matching zolpidem tartrate sublingual tablet taken either 3 or 4 hours prior to driving. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching zopiclone
Study: NCT04397653

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ezetimibe
Description: Ezetimibe 10 mg daily will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia in both the placebo arm (plus placebo) and in the intervention arm (plus evolocumab)
Study: NCT01106859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching zopiclone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching zopiclone
Study: NCT02628431

Intervention type: DEVICE
Intervention: Elfi tech monitor

Intervention type: DEVICE
Intervention: Elfi tech monitor
Study: NCT00258765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Study: NCT06277414

Intervention type: OTHER
Intervention: collection of laboratory test results, imaging results and symptoms
Description: collection of laboratory test results, imaging results and symptoms
Study: NCT04894344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education group
Description: Is taught to choose low-sodium foods
Study: NCT01220323

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: direct current stimulation
Description: Patients will receive sham tDCS or real tDCS in a 5-day period of treatment in a randomized, sham controlled study. The participants will be divided to 2 groups of 50 each. One group will receive 5 days period of 20 min 2mA tDCS over the lt M1 and the other will receive sham stimulation. X week later the groups will switch to the other arm

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: direct current stimulation
Description: Patients will receive sham tDCS or real tDCS in a 5-day period of treatment in a randomized, sham controlled study. The participants will be divided to 2 groups of 50 each. One group will receive 5 days period of 20 min 2mA tDCS over the lt M1 and the other will receive sham stimulation. X week later the groups will switch to the other arm
Study: NCT02280785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: Brentuximab vedotin must not be administered as an IV push or bolus. It must be administered in 100ml-250ml of 0.9% saline by intravenous infusion over 30 minutes once every 3 weeks.
Study: NCT01842477

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantation of bone substitute plus autologous cultured mesenchymal cells
Description: Implantation surgery of a synthetic bone substitute associated with autologous bone marrow cells expanded